Biogen (NASDAQ:BIIB) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the ...
Or is the biotech's best days in the rearview mirror?
Biogen (NASDAQ:BIIB) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the ...
Dealbreaker on MSN
Why Biogen is paying $5.6B to buy Apellis Pharma
CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions.
Biogen has just launched a new app, called Aby, aimed at giving people living with multiple sclerosis (MS) accurate and reliable information about the condition and support. The app is free and gives ...
Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...
The European Medicines Agency (EMA) on Friday announced it is provisionally restricting the use of Biogen Idec’s multiple sclerosis (MS) medicine Zinbryta (daclizumab) to patients with highly active ...
Biogen updated the label for its best-selling oral multiple sclerosis drug Tecfidera to include a warning about risk of liver injury that can occur when taking the drug, reports Reuters. The label ...
Biogen Inc. forecast 2026 profit above Wall Street’s expectations, signaling that steep cost-cutting measures are cushioning the impact of shrinking sales from its multiple sclerosis franchise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results